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Abstract
Adrenocortical tumors consist of benign adenomas and highly malignant carcinomas with a still incompletely
understood pathogenesis. A total of 46 adrenocortical tumors (24 adenomas and 22 carcinomas) were investigated
aiming to identify novel genes involved in adrenocortical tumorigenesis. High-resolution single nucleotide
polymorphism arrays (Affymetrix) were used to detect copy number alterations (CNAs) and copy neutral losses of
heterozygosity (cnLOH). Genomic clustering showed good separation between adenomas and carcinomas, with best
partition including only chromosome 5, which was highly amplified in 17/22 malignant tumors. The malignant tumors
had more relevant genomic aberrations than benign tumors, such as a higher median number of recurrent CNA
(2631 vs 94), CNAs >100 Kb (62.5 vs 7) and CN losses (72.5 vs 5.5), and a higher percentage of samples with
cnLOH (91% vs 29%). Within the carcinoma cohort, a precise genetic pattern (i.e. large gains at chr 5, 7, 12, and 19,
and losses at chr 1, 2, 13, 17, and 22) was associated with a better prognosis (overall survival: 72.2 vs 35.4 months,
P=0.063). Interestingly, >70% of gains frequent in beningn were also present in malignant tumors. Notch signaling
was the most frequently involved pathway in both tumor entities. Finally, a CN gain at imprinted “IGF2” locus chr
11p15.5 appeared to be an early alteration in a multi-step tumor progression, followed by the loss of one or two
alleles, associated with increased IGF2 expression, only in carcinomas. Our study serves as database for the
identification of genes and pathways, such as Notch signaling, which could be involved in the pathogenesis of
adrenocortical tumors. Using these data, we postulate an adenoma-carcinoma sequence for these tumors.
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Introduction
Adrenocortical tumors consist of highly prevalent adenomas
(ACA) and rare carcinomas (ACC), which both can be either
endocrinologically silent or hormonally active. ACC is a highly
aggressive tumor with poor prognosis and an overall survival
rate of 5 years of 25–50% in most series [1,2,3,4,5,6]. The
rarity of ACCs is a major limitation to our understanding of their
pathophysiology. Accordingly, the genetic mechanisms
underlying adrenocortical tumor development are still largely
unknown. In particular, it is still unclear whether ACCs evolve
from ACAs following a second-hit paradigm. Although such a
sequence has been occasionally observed [7], long-term
follow-up of incidentally discovered adrenocortical neoplasms
suggests that ACAs generally maintain a benign phenotype
[8,9]. In addition, a recent study described a mouse model in
which dysregulation of one pathway (i.e. β-catenin
accumulation or IGF2 overexpression) may result in adrenal
hyperplasia, but a second hit or multiple alterations appear to
be necessary for tumorigenesis [10]. Moreover, distinguishing
malignant from benign tumors remains a clinical dilemma as
only the combination of several markers allows a clear-cut
histological differentiation [11]. Thus, the diagnosis of ACC still
requires histological examination and scoring by a highly
experienced pathologist. The profound differences in treatment,
follow-up and prognosis between benign and malignant adrenal
PLOS ONE | www.plosone.org 1 September 2013 | Volume 8 | Issue 9 | e73959
lesions make the correct classification of adrenocortical tumors
of utmost importance.
Molecular studies of inherited syndromes with increased risk
of ACC, coupled with recent advances in expression profiling,
have improved our understanding of the genetic mechanisms
underlying ACC development [12,13,14,15]. For instance,
microsatellite markers revealed common inactivating mutations
or loss of heterozygosity (LOH) at 17p13, a region that includes
the TP53 tumor suppressor gene, LOH at 11q13 (MEN1 locus),
and alterations of the imprinted 11p15 locus (paternal
isodisomy) leading to IGF2 overexpression [16,17]. Finally,
constitutive activation of β-catenin is a common alteration in
both ACA and ACC, being likely involved in both adrenocortical
development and neoplasia [18].
Copy number alterations (CNAs) have also been described
in adrenal hyperplasia, ACA and ACC using fluorescence in
situ hybridization (FISH), karyotyping, and either conventional
comparative genomic hybridization (CGH)
[19,20,21,22,23,24,25] or array-based CGH [23,26,27]. In
particular, losses at 1p, 2q, 3p, 6q, 9, 11, 17p, and 18q and
gains at 4, 5, 12q, 16, 19 and 20q have been reported in
patients with sporadic ACC, some of them being associated
with a poor prognosis [28]. Taken together, gene expression
and CGH studies have shown that several pathways are
dysregulated in ACC affecting cell cycle, retinoic acid signaling,
lipid metabolism, complement system, and antigen
presentation [13,28,29]. However, results from CGH studies
have been variable and restricted to large regions not allowing
the identification of candidate genes associated with disease
initiation or progression. Of note, most of the molecular
candidates so far proposed as diagnostic or prognostic
markers, like ERCC1 [30], GLUT1 [31] and MMP2 [32] have
not yet been confirmed in subsequent studies, with the
significant exception of the steroidogenic factor 1 [33,34].
In contrast to CGH, the single nucleotide polymorphism
(SNP) microarray technique allows detection of both genome-
wide CN data and LOH events [35]. By merging these two
analyses, it is possible to identify copy neutral LOH (cnLOH, or
uniparental disomy, UPD), a chromosomal defect which
comprises 50-70% of all LOH events detected in human tumors
[36]. Furthermore, recent high resolution SNP array platforms
can identify amplifications/deletions at a single gene level,
offering a powerful method for oncogene and tumor suppressor
gene discovery [37,38,39]. Recently, we applied this method to
investigate the genetic events in a group of 15 benign cortisol-
secreting tumors, detecting several recurrent CN gains and
losses, mostly microalterations, in both already known and
newly identified chromosomal regions. In addition, we reported
novel genes (i.e. HRAS, EPHA7, and SGK1) and pathways
(i.e. Notch signalling pathway) that could be involved in early
tumorigenesis [40]. Another recent study on childhood
adrenocortical tumors also using SNP array profiling identified
some amplified oncogenes and deleted tumor suppressor
genes and demonstrated different oncogenic routes [41].
In the present study, we used high-resolution SNP
microarrays to investigate a larger series of benign and
malignant adrenocortical tumors with the major aim to identify
new candidate genes that could be suggestive for an
adenoma-carcinoma sequence (i.e. alterations common
between ACA and ACC). Furthermore, we also intended to




The study was approved by the ethics committee of the
University of Würzburg (permits No. 93/02 and 88/11) and
written informed consent was obtained from all patients.
Study population
A total of 50 adrenocortical tumors with matched blood
samples were selected for the present study independent of
the hormonal status (26 samples from ACC patients and 24
samples from ACA patients). Clinical parameters, such as sex,
age at diagnosis, date of surgery, tumor size, pathological
classification, and results of hormone analysis were collected
from patient records. Malignancy was defined according to
established clinical, biochemical, and morphological criteria
[42], while the biochemical diagnosis of cortisol hypersecretion
was made according to established guidelines [43]. For ACC
patients, additional data, such as tumor stage according to the
ENSAT (European Network for the Study of Adrenocortical
Tumors) classification, Weiss score, MIB1 (Ki67 index),
presence and number of distant metastasis, follow-up duration,
overall and disease free survival, type and response to
treatment, was collected from the German ACC Registry
[30,44].
Tissue samples and DNA extraction
Tumor tissue specimens collected from patients operated
between 1993 and 2011 were used for the present study.
Corresponding blood samples were collected from all patients.
Normal adrenal tissue surrounding the tumor was also
available for 17 out of 53 patients. Tumor, blood and normal
adrenal samples were stored at -80°C in our department
(University Hospital, Wuerzburg, Germany). Genomic DNA was
extracted using standard procedures (QIAamp DNA Mini and
Blood Mini Kit, Qiagen, Hilden, Germany). Only samples with
appropriate DNA quality as measured by Bioanalyzer 2100
(Agilent Technologies, San Jose, CA, USA) were further
evaluated.
SNP arrays and data analysis
SNP array experiments were performed using the high-
resolution Affymetrix GeneChip Human Mapping 6.0
microarray (SNP 6.0, Affymetrix Inc., Santa Clara, CA, USA),
as previously reported [40]. Affymetrix raw intensity data (.CEL
files) were generated by the command console and quality
control (QC) was assessed by the Genotyping Console
software (GTYPE version 4.0, Affymetrix, Santa Clara, CA).
Only arrays were accepted that had a QC of 1.7 or higher and
a MAPD of 0.3 or smaller, as recommended for large study
sets.
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The CN analysis was performed using the Partek Genomics
Suite software package (Partek GS, Version 6.5, Partek
Incorporated, St. Louis, MI, USA, www.partek.com), as
previously published [38,40]. A preliminary unpaired data
analysis was performed in all samples (50 tumors, 50 blood
samples and 17 normal adrenal tissues surrounding the
tumors). Unexpectedly and for no obvious reasons, 8 blood
samples (16% of total) showed a large number of CNAs.
Similar results were obtained after repeated blood sampling,
hybridization and data analysis. In four of these 8 cases, the
tissue surrounding the tumor was available and was taken as
normal reference, while the remaining 4 samples were
excluded from further analysis. The paired CNA analysis was
carried out by comparing the intensity of the hybridization
signal from a tumor sample to that of the matched normal DNA.
The genomic clustering was performed by unsupervised
euclidean distance clustering (complete linkage), while regions
of CNA were detected by a genomic segmentation algorithm,
as previously described [40]. A false-discovery-rate based
adjustment was always applied using the step up method with
an alpha value of 0.05 (Benjamini and Hochberg, 1995).
Genotype analysis was performed using the Birdseed v2
algorithm (Affymetrix GTC, version 4.0), according to the
recommended instructions. The SNP call rate after genotype
analysis was >95% in all samples. For the LOH analysis, CHP
files were imported into the Partek GS and the hidden Markov
model algorithm was applied [40]. The LOH data were merged
with CNAs in order to obtain the cnLOH, as previously reported
[40].
The Partek workflow and the Hg19 (reference file) were used
for the gene annotation (RefSeq). The observed CNAs were
checked against the database of genomic variants (dBVar).
Gene ontology (GO) enrichment and gene family analysis of
gene sets was performed using the gene set enrichment
analysis (GSEA) annotation tool (www.broadinstitute.org/gsea).
Relevance of altered genes to currently known canonical
pathways was investigated using the MetaCore Analytical suite
(Pathways Maps, GeneGo Inc., Thomson Reuters, St Joseph,
MI, USA, thomsonreuters.com/products_services/science/
science_products/a-z/metacore). In particular, MetaCore was
used to calculate the statistical significance (P value) of the
probability of assembly from a random set of nodes (genes) of
the same size as the input list (single experiment analysis). A
P<0.02 indicates a statistically significant non random
association. The same software was used to characterize the
top scored gene networks.
Correlation to clinical data
The comparison of clinical parameters, such as age at
diagnosis, tumor size, hormonal secretion pattern, tumor stage
(ENSAT), Weiss score, and the proliferation index MIB1 (Ki67
index), and presence of distant metastasis between groups
with or without genetic alterations were performed by
appropriate statistical methods. The Fisher’s exact test or the
Chi-square test was used to investigate the relationship
between dichotomic variables, while a one-way ANOVA model
or a two-sided t test was used to test continuous variables.
Correlations between different parameters were evaluated by
linear regression analysis. Survival analysis was calculated
using the Kaplan-Meier method and differences between
groups were assessed with log-rank statistics. Overall survival
(OS) was defined as the time from the date of the primary
tumor excision to date of death or last analysis. A multivariate
regression analysis was performed by Cox proportional hazard
regression model. Statistical analyses were performed using
GraphPad Prism (version 4.0, La Jolla, CA, USA) and SPSS
Software (PASW Version 19.0, SPSS Inc., Chicago, IL, USA).
P values <0.05 were considered as statistically significant.
FISH analysis
Selected CNAs identified by SNP array results were
validated on paraffin-embedded tumor tissue samples (12 ACA
and 10 ACC) using fluorescence in situ hybridization (FISH)
analysis according to previously published methods [45].
Specifically, BAC clones (Children’s Hospital Oakland
Research Institute) were used. They were labeled with
fluorophores, fragmented and hybridized together with the
corresponding centromer-specific reference probe (Vysis,
Abbott Molecular, IL, USA). The probes chosen for the region
5q-5p, largely amplified in ACC according to the SNP array
results, were CSF1R/D5S23 and D5S721. A total of 100
interphase nuclei were analyzed with a Zeiss Axioskop 2
Microscope (Carl Zeiss MicroImaging) by two independent
operators and a ratio of red signals (specific probes 5q-5p) to
green signals (centromeric probes) was calculated. The cut-off
for defining gains or losses was >40% cells.
Quantitative real time PCR (qRT-PCR)
RNA was isolated from frozen tumor tissue samples for
expression analysis (16 normal adrenal, 18 ACA, and 14 ACC)
using the RNeasy Lipid Tissue Minikit (Qiagen) and reverse
transcribed using the QuantiTect Reverse Transcription Kit
(Qiagen). Predesigned Taqman® gene expression assays for
IGF2 gene (Hs00171254_m1) were purchased from Applied
Biosystems (Darmstadt, Germany). Endogenously expressed
β-actin (Hs9999903_m1) was used for normalization. 40 ng
cDNA was used for each PCR reaction and each sample was
performed in duplicate. Transcript levels were determined by
using the TaqMan Gene Expression Master Mix (Applied
Biosystems), the C1000 Thermal Cycler (CFX96 real-time
system, Biorad) and the Bio-Rad CFX Manager 2.0 software.
Cycling conditions were 95° for three min followed by 50 cycles
of 95° for 30 sec, 60° for 30 sec, and 72° for 30 sec. Using the
∆CT method [46], the gene expression levels were normalized




The final study cohort included 46 adrenocortical tumor
tissues with matched normal samples (42 from blood samples
and 4 from adrenal tissue surrounding the tumors). Specifically,
24 patients with ACA (13F & 11M, mean age at diagnosis:
50±14 yrs, 16 cortisol-secreting) and 22 patients with ACC
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(14F & 8M, mean age at diagnosis: 46±14 yrs, 15 cortisol-
secreting) have been investigated. The detailed clinical,
pathological and corresponding genetic characteristics of the
ACA and ACC groups are provided in Table 1.
SNP array profiling may differentiate benign from
malignant adrenocortical tumors
Principal component analysis (PCA) and genomic
clustering.  The PCA showed a good separation of the ACCs
from the ACAs, previously classified according to established
morphological criteria (Figure S1). The unsupervised genomic
clustering including the most altered chromosomes (i.e. chr 1,
5, 7, and 12) could separate well ACAs from ACCs. This was
even more evident when considering only chr 5. In particular,
17/22 ACCs (77%) presented gains involving more than 60% of
chr 5, while the ACAs had only few sparse small alterations
(consisting of both gains and losses) (Figure 1A). Specifically,
large amplifications at chr 5 at the SNP arrays analysis allowed
us to recognize ACC with a sensitivity of 77.3% and a
specificity of 100% (positive and negative predictive values:
100% and 82.2%, respectively).
The genetic alterations at the chr 5 were further validated by
FISH analysis (Figure 1B), which confirmed the presence of
5p/5q amplifications in 10/10 ACCs (>50% of evaluated cells in
8/10 ACCs). In addition, 5p/5q amplifications were also
observed by FISH in 3/12 ACAs (P<0.05 vs ACC), but only one
benign tumor showed this alteration in >50% of evaluated cells.
Table 1. Summary of clinical features and genetic
alterations observed by the SNP microarray analysis of 46
patients with adrenocortical tumors.
 Adenoma Carcinoma P
N 24 22  
Clinical parameters    
Sex (M/F) 11/13 8/14 NS
Age (yrs) – median (range) 49.5 (17-71) 46.5 (18-72) NS
Tumor size (cm) – median (range) 4.0 (2-11) 10.5 (4-23) <0.001
Hormonal pattern   NS
Nonsecreting (n) 8 3 -
Cortisol-secreting (n) 16 15 -
Aldosteron-secreting (n) - 1 -
Androgen-secreting (n) - 3 -
Tumor stage (ENSAT)   -
ENSAT 1-2 (n) - 12 -
ENSAT 3 (n)  4 -
ENSAT 4 (n)  6 -
Genetic alteration    
CNA - median (range) 43.5 (1-688) 132 (28-773) NS
Gains - median (range) 27.5 (0-665) 68.5 (12-376) NS
Losses - median (range) 5.5 (0-578) 72.5 (16-726) 0.06
Large CNA* – median (range) 7.0 (0-299) 62.5 (8-499) <0.01
cnLOH - median (range) 0 (0-13) 4333 (0-8655) <0.0005
CNA=copy number alterations, cnLOH= copy neutral loss of heterozygosity. * more
than 100 Kb.
doi: 10.1371/journal.pone.0073959.t001
This adenoma also presented some histo-pathological signs of
malignancy, such as large and highly pleomorphic nuclei,
eosinophilic and pigmented cytoplasm, a central
mylolipomatose metaplasia and a proliferation index (Ki67) of
2%. These results imply a role for the amplification of almost
the entire chr 5 in adrenocortical tumorigenesis and suggest it
as a new potential diagnostic marker.
No differences were observed in terms of clustering between
cortisol-secreting and non cortisol-secreting tumors or among
different tumor stages in ACC.
Paired CNA analysis.  All tumors had at least one
aberration and the total number of CNAs was slightly higher in
ACCs than in ACAs (median per sample: 132 vs 43.5, P=0.19,
Table 1). However, 11/24 ACAs and 21/22 ACCs presented at
least 50 CNAs along the entire genome (P<0.05). In
comparison with benign tumors, the malignant ones showed a
higher proportion of CN losses (55% vs 31%, P=0.001) and of
large CNAs (>100 Kb, 56% vs 25%, P<0.01). The genome-
wide distribution of the CNA in each tumor sample is provided
in the Figure 2A. The entire list of detected CNAs and their
characteristics, including corresponding genes is provided in
Table S1. No significant correlation was observed between the
total number of CNA and the clinical parameters.
Aiming to focus on genetic alterations with possible biological
significance, we further considered only the CNAs found in
chromosomal regions coding for known genes and were
observed in at least 4 samples (minimal overlapping regions,
frequency >15%, Figure 2B, Table S2). These recurrent
alterations were more frequent in ACC (1680 gains and 951
losses) than in ACA (94 gains and no losses). Only few
recurrent CN gains, involving 13 chromosomal regions, were
detected only in benign tumors, but not in ACC. Most of them
were microalterations, except those at 1p36.33, 8q24.3
(including CYP11B2), and 11p15.5 (including IGF2 and INS),
which ranged from 1000 to 4000 Kb. Interestingly, most of
these regions were also altered among ACCs, but they were
affected by losses instead of gains (excluding chr 2q24.2,
3p24.1, 8q24.3, 10q24.32).
LOH analysis.  23 LOH events were detected in 7/24 ACA
(29%), none being present in more than one sample, while a
high number of LOH events were distributed over the whole
genome in 20/22 ACCs (91%, Table 1 and Figure 3A). The
total number of LOH significantly correlated with tumor size
considering all tumors together (P<0.01, r=0.41, Figure 4).
Merging the CNA with the LOH analysis, we observed that in
ACAs only one LOH event was associated with a CN loss (at
Xq21.1, noncoding), while 5 were associated with a CN gain
and 17 were copy neutral LOH (cnLOH) events (Figure 3B). A
similar proportion of cnLOH was found among LOH also for
ACCs (n=5848, Figure 3B). The simultaneous presence of
more than 50 large CNA (>100 Kb) and more than 10 cnLOH
events was specific for ACC (18/22 ACC vs 0/24 ACA,
sensitivity 82% and specificity 100%; positive and negative
predictive values: 100% and 85.7%, respectively, Figure 5).
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Figure 1.  Copy number amplifications in chromosome 5 are specific for malignant adrenocortical tumors.  A) Unsupervised
euclidean distance genomic clustering (complete linkage) in 46 adrenocortical tumor samples (defined as sample ID). Best
separation between adenoma (ACA, n=24, white) and carcinoma (ACC, n=22, black) obtained analyzing only the chromosome 5.
B) Validation with FISH analysis of the copy number alterations detected with SNP array in chromosome 5. Two representative
adrenocortical carcinomas (ACC, samples ID 456C and 1023C) with gains/amplifications at SNP array analysis validated by FISH
(probe FISH_5q/5p-Probe: CSF1R/D5S23, D5S721). Gain of the red signal (specific probe) with respect to the green signal
(centromer-specific reference probe) in more than 50% of cells. In black the ACC patients affected by ACC and in white the patients
affected by ACA.
doi: 10.1371/journal.pone.0073959.g001
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Figure 2.  Whole-genome copy number alterations (CNA) in adrenocortical tumors.  A) Genome-wide distribution of CNA in
each adrenocortical tumor according to the genomic segmentation algorithm (Partek GS). ACA=adenoma (n=24, total number of
CNA=3603). ACC=carcinoma (n=22, total number of CNA=5017).
B) Genome-wide distribution of recurrent CNA in adrenocortical tumors. Minimal overlapping regions in at least 4 samples (MORs,
frequency >15%). ACA=adenoma (n=24, total number of CNA=283). ACC=carcinoma (n=22, total number of CNA=3993).
CN gains are represented in red and CN losses in blue.
doi: 10.1371/journal.pone.0073959.g002
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Figure 3.  Whole-genome loss of heterozygosity (LOH) events in adrenocortical tumors.  A) Genome-wide distribution of LOH
events in each adrenocortical tumor according to the hidden markov model (Partek GS). ACA=adenoma (n=24, total number of
LOH=23). ACC=carcinoma (n=22, total number of LOH=2439).
B) Genome-wide distribution of copy neutral LOH identified by merged analysis between copy number alteration and LOH analysis.
doi: 10.1371/journal.pone.0073959.g003
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Specific gains/microamplifications might be early
events in tumorigenesis
More than 70% of recurrent CN gains detected in the ACA
were present also in ACC (Table S3). Specifically, we observed
81 common CN gains, mostly involving chr 5p13.33, 9q32-34,
16p13.3, and 19p13-12, among whom 43 were
microamplifications. These shared altered regions code for 696
genes recognized in GO, the most interesting being reported in
Table 2. Among these genes, 11 cytokines and growth factors,
41 transcription factors (including NR5A1 coding for
steroidogenic factor 1), 16 protein kinases, 11 known
oncogenes (including HRAS and NOTCH1) and 4 known tumor
suppressor genes were recognized. The Notch1 signaling was
recognized as the most frequently altered pathway (P<0.005),
followed by the anti-apoptotic TNFs/NF-kB/IAP pathway
(P<0.05) and by the WNT5A signaling (P<0.05) (Figure 6A-C),
while the gene network analysis identified the Wnt receptor
signaling as the most relevant network (Figure 2S A and B).
In addition, several of these genes commonly gained in ACA
and ACC are known or supposed to be associated with the
Wnt/beta catenin signaling pathway (i.e. APC2, CSNK1G2,
AXIN1, NKD2, CSNK1P, EMD, VAV2), the Notch signaling
pathway (i.e. LFNG2, RFNG, NRARP, NKD2, MIR199B,
NDUFS7, TCFLS), the mTOR pathway (i.e. MAPKAP1, TSC1,
TSC2, RPTOR, PPAPDC3, MLST8) or the p53 pathway (i.e.
E4F1, GPS1, MRPL41, ARID3, GAMT). A number of these
genes (n=18) have been previously associated with resistance
Figure 4.  Correlation between the total number of LOH
events and tumor size.   All the evaluated adrenocortical
tumors (n=46) were included in the analysis by linear
regression analysis. White triangles = adenomas (n=24), black
triangles = carcinomas (n=22).
doi: 10.1371/journal.pone.0073959.g004
to chemotherapy in other cancer types (i.e. among others
PDCD6, ENDOG, BIRC7, CIRBP, ABCA7, MBD3, TCF3,
ORM1, FLNA, NEX6, TUBB3, ABCA2). Finally, 26 microRNAs
were also on the list of common altered gene as were some
other interesting genes, such as the orphan enzyme CYP2W1
and the PRKAR1B coding for the regulatory subunit 1 beta of
the protein kinase A.
Finally, 121 cnLOH events, involving 61 different regions on
chr 1p, 1q, 9, 10q, 11p, 14q, 16q, Xp, and Xq, were similar
between ACA and ACC (see Table S4). They code for 618
genes recognized in GO, including 10 cytokines and growth
factors, 59 transcription factors, 16 protein kinase, 8
oncogenes (FOXO4, MSN, MYST4, SSX1, SSX2, SSX4, STIL,
TFE3), 3 tumor suppressor genes (FAM123B, KDM5C,
KDM6A), and 64 microRNAs (including MIR503). Genes
commonly affected by cnLOH were mainly involved in
neurotrophin family signaling, pathways related to cell cycle
(sister chromatid cohesion), immune response (IL2 and IL3
activation), and cell adhesion (ECM remodelling). The gene
network analysis identified the toll-like 1 and 2 signaling
pathway as the most frequently affected (P<0.0005).
Genetic alterations at the 11p15.5 locus as example of
adenoma-carcinoma sequence
As expected according to the current knowledge, a large
percentage of our ACCs presented an LOH event in a segment
at the imprinted chr 11p15.5 locus, which included the genes
IGF2, IGF2AS, INS, INS-IGF2, and MIR483. In particular,
12/22 cases had a cnLOH (54% of total) and other 5 cases had
an LOH associated with CN loss (23%). Interestingly, we also
observed in the same locus an isolated CN gain in 2/22 ACC
(9%) and in 6/24 ACA (25%).
The relative IGF2 mRNA expression was also evaluated in
our samples and correlated with the CN status. Specifically, we
found that the IGF2 levels were similar between ACAs and
normal adrenals, independently from the genetic alterations.
On the other hand, IGF2 expression was significantly increased
in ACC (P<0.001), especially in those samples affected by
cnLOH or LOH associated with CN losses (Figure 7A), thus
suggesting a possible multistep genomic aberration at this
locus (i.e. first a duplication of the paternal allele followed by
the loss of the maternal allele and as late step by the loss also
of one paternal allele). However, probably due to the small
number of patients included in each subgroup, we were not
able to find any significant correlation between the specific
genetic alterations at the IGF2 locus and the clinical data (such
as tumor size or stage).
Enrichment analysis shows specific altered pathways
in ACC
The gene family analysis performed for all the frequently
altered genes is reported separately for adenomas and
carcinomas in the Table S5.
We focused on the aberrations specific for ACC and included
only the genes specifically altered in ACC in further analysis.
Among the gained genes (n=11415 recognized in GO), we
identified over 160 known oncogenes (including ABL1, AKT1-2,
BRAF, EGFR, FGFR1-3, GNAS, JAK2-3, KIT, MYC, NOTCH1,
CN Alterations and LOH in Adrenocortical Tumors
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and RET). On the other side, 20 tumor suppressor genes
(including BRCA1-2, ERCC5, MEN1, RB1 and TP53) were
identified among the lost genes (n=3717 recognized in GO)
and 67 tumor suppressor genes (including ERCC3, and TP53)
were identified among the genes affected by cnLOH.
The most frequently altered pathways were related to cell
adhesion, apoptosis and survival, cytoskeleton remodeling,
development, and signal transduction when considering the
gained genes (Figure S3 A) and mainly involved cytoskelton
remodeling and immune response when considering the lost
genes (Figure S3 B). Finally, the pathway analysis showed as
most affected by cnLOH the cytoskeleton remodeling (TGF,
WNT, and cytoskeleton remodeling, P<0.0001), immune
response (HSP60 and 70/TLR, P<0.0001, and HMGB1/TLR
signaling, P<0.001), and cell adhesion (chemokines and
adhesion, P<0.001).
A specific CNA pattern might have prognostic value in
ACC
Searching for a possible prognostic value of genetic
alterations, we also performed an unsupervised genomic
clustering including only the ACCs. We identified a specific
combination of chromosomal alterations which allowed us to
separate the malignant tumors into different clusters (see
Figure 8A). In particular, the tumors included in the clusters 1a
(n=8) and 1b (n=5) behaved quite similar presenting several
large amplification at chr 5, 7, 12, and 19, and large deletions
at chr 1, 2, 13, 17, and 22, while the 9 other tumors showed an
extremely variable pattern of genetic alterations. The
Figure 5.  Schematic representation of the genetic alterations detected by SNP array analysis in adrenocortical tumors.  In
the upper panel, the percentage of samples affected by different alterations is reported. Interestingly, the simultaneous presence of
numerous LOH and large CNA was observed only in malignant tumors (n=22). In the lower panel, some relevant specific alterations
in candidate genes and pathway are reported. In particular, some alterations were observed in all tumors (i.e. isolated small CN
gains), while others were found only in carcinomas.
CNA=copy number alterations, LOH=loss of heterozygosity) detected by SNP array analysis in adrenocortical adenomas (n=24) and
carcinomas (n=22).
doi: 10.1371/journal.pone.0073959.g005
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Table 2. List of chromosomal regions affected by most
frequent copy number gains in both adrenocortical
adenomas (ACA, n=24) and carcinomas (ACC, n=22). A






ACC Selected corresponding genes
5p15.33 5 18 AHRR, PDCD6, SDHA, NKD2
 5 16 TERT, CLPTM1L





19p13.3 4 11 CIRBP, STK11
 4 10 GNG7
 4 10
ABCA7, BSG, FSTL3, KISS1R,
APC2, DOT1L, GADD45B,
MKNK2, TCF3
7p22.2 5 11 GNA12
 6 11 NUTD1
7p22.2-22.3 7 11 CYP2W1, GPER, GPR146,PDGFA, PRKAR1B
9q32 4 11 PRPF4, SLC31A1
9q32-33.1 4 11 ORM1, TNFSF15
9q33.1 4 10 DEC1
9q33.2 4 11 DAB2IP
 4 10 PTGS1
9q33.3 4 10 HSPA5, SCAI
9q33.32-33.3
3 4 10 NEK6, NR5A1
9q33.3-34.11 4 10 CDK9, ENG, LCN2
 4 8 SPTAN1
 4 9 ABL1, ASS1, ENDOG, FNBP1,NUP214, PKN3, SET
9q34.13-34.2 4 10 RALGDS, RPL7A, TSC1
9q34.2 5 10 BRD3, WDR5
 4 10 VAV2
9q34.2-34.3 5 10 RXRA
9q34.3 5 9 EGFL7, NOTCH1, TRAF2,NRARP
9q22.31 4 10 WNK2
Xq28 5 9 CTAG1B, FLNA, G6PD, L1CAM,TAZ, TKTL1
16q24.3 5 9 ANKRD11
 6 8 FANCA, GAS8, TUBB3
 5 8 CDK10, CHMP1A, DPEP1
Xp22.33 6 6 CRLF2, P2RY8
16p13.3 7 6 SSTR5
relationship with the clinical data showed that the first group
(clusters 1a+1b) had smaller tumor size (9.2±4.2 vs 13.2±5.0
cm, P=0.10), lower Weiss score (5.0±1.9 vs 6.8±1.0, P=0.018)
and lower ENSAT tumor stage (ENSAT 1-2: 61% vs 44%,
P=0.016). In addition, they also had a longer overall survival in
comparison with the other cluster groups (median survival: 72.2
vs 35.4 months, P=0.063, HR=5.22, 95%CI=0.91-25.9, Figure
8B). However, this difference was lost when including the
genetic pattern in a multivariate analysis together with the
ENSAT tumor stage and the Ki67 index.
Discussion
We here provide for the first time a genome-wide high-
resolution overview of chromosomal changes in a large series
of adrenocortical tumors, including adenomas and carcinomas.
In a previous pilot study we already observed in a small group
of benign cortisol-secreting tumors frequent CN gains in newly
reported chromosomal regions (i.e. 8q24.3, 11p15.5, Xq28)
and promising candidate genes or pathways potentially
involved in early tumorigenesis [40]. In the present paper, we
identify some pathways, such as Wnt/β-catenin and Notch
signaling, commonly altered in ACA and ACC, strengthening
our previous hypothesis that these pathways are involved in
early tumor pathogenesis. Moreover, we recognize some
genetic aberrations specific for ACC, such as the amplification
of the chr 5, recurrent large CNA (mostly losses), and frequent
LOH and cnLOH events distributed all over the genome, that
could be used as markers of malignancy. In addition, we
identify a specific genetic pattern associated with a better
prognosis.
Alterations suggestive for an adenoma-carcinoma
sequence (similar between ACA and ACC)
A recent study by Heaton et al. inducing stabilized beta-
catenin and elevated Igf2 expression in mice suggested a
multistep model whereby normal adrenal glands become first
hyperplastic and then progress to ACA and ACC [10]. Single
cases with the presence of an aggressive ACC embedded
within ACA tissue are also suggestive for such a multistep
progression [7,47]. However, due to the obvious discordance
between the frequency of ACA and the rarity of ACC most









 7 5 AXIN1
 6 5 E4F1
17q25.3 4 4 ASPSCR1




CN Alterations and LOH in Adrenocortical Tumors
PLOS ONE | www.plosone.org 10 September 2013 | Volume 8 | Issue 9 | e73959
Figure 6.  Pathway analysis for genes frequently affected by copy number alterations in both adenomas and
carcinomas.  A) List of the most significantly altered pathways according to the GeneGo analysis (Meta Core Analytical suite)
including all the genes (n=696 annotated genes) with copy number alterations observed in at least 4 samples (recurrent CNA) in
both adenomas and carcinomas. The P values are expresses as logarithmic scale. B) Graphical representation of the Notch
signaling pathway map (gene ontology enrichment, P=2.913e-4).
C) Graphical representation of the WNT5 signaling pathway (gene ontology enrichment, P=3.256e-3).
Genes with gains are underlined in red and genes with losses in blue. Detailed legend is available at http://pathwaymaps.com/pdf/
MC_legend.pdf.
doi: 10.1371/journal.pone.0073959.g006
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Figure 7.  Relationship between genomic alterations at chr 11p15.5 and IGF2 gene expression in adrenocortical tumors.  A)
Relative mRNA expression levels evaluated by qRT-PCR for IGF2 gene according to the copy number status observed with SNP
array analysis in normal adrenals (n=16), adenomas (n=18) and carcinomas (n=14). The gene actin beta was used as a loading
control (reference gene). Data expressed as logarithmic scale. P=0.0003 by one-way ANOVA.
B) Schematic representation of the genetic alterations at the 11p15.5 imprinted locus and their impact on IGF2 expression levels. In
particular, we firstly report frequent copy number gains in adenomas, leading to a normal IGF2 expression, and we confirm frequent
copy neutral LOH events in carcinoma, leading to an increased IGF2 expression, suggesting a progressive multi-step genetic
derangement in this locus. We also demonstrate a further allele loss in carcinoma (LOH + CN loss) without effects on IGF2
expression.
doi: 10.1371/journal.pone.0073959.g007
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Figure 8.  Relationship between genomic alterations and clinical outcome in malignant adrenocortical tumors.  A)
Unsupervised euclidean distance genomic clustering (complete linkage) in 22 carcinomas. Best cluster obtained including a specific
combination of chromosomes (i.e. chr 1, 2, 4, 5, 7, 12, 13, 14, 17, 18, 20, 22, and X).
B) Relationship between the genetic clusters and the clinical parameters: tumor size and Weiss score (Mann-Withney test), ENSAT
tumor stage (Fisher’s test) and overall survival (Kaplan-Meyer curve and log-rank test).
In black the patients with a worst prognosis (overall survival < 24 months), in grey the patients with an intermediate prognosis
(overall survival 24-48 months), and in white the patients with a good prognosis (overall survival > 48 months or still alive at the last
follow up).
doi: 10.1371/journal.pone.0073959.g008
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like it is well established in colon tumors [48]. Several of our
present findings support now the evidence of an adenoma
carcinoma sequence for adrenocortical tumors.
First, about half of our ACA samples and almost all the ACC
samples presented in average similar numbers of CNA along
the entire genome. Among the benign tumors, small isolated
CN gains were the most frequent genetic alterations and
almost all of them were also present in several ACC (Table 2).
Many of these aberrations have already reported in other
cancer types. For instance, frequent gains at 5p13.3 and
20q11-13 have been described in early stage NSCL cancer
and in colorectal tumors [49,50,51], suggesting a potential role
of these as a first step in tumor progression. In addition, gains
at chr 7p22, 9q22.3, and Xq28 have been already described in
other early-stage cancers [50,52,53,54,55]. Finally, recurrent
gains at 8q24, 9q33-34 and 19p13-q13 have been also
similarly reported in childhood adrenocortical tumors [41].
Second, some canonical pathways, such as the Wnt/beta
catenin and the Notch1 signalling, were frequently affected by
CN gains in both ACA and ACC. The Wnt/beta catenin
pathway is known to be activated in adrenocortical tumors and
to be involved in adrenal development and tumorigenesis [56],
but until now no CNA have been reported in this pathway. On
the other hand, the Notch signalling pathway has not been yet
directly associated with tumor development and progression in
ACC. Furthermore, Notch and Wnt/beta-catenin signalling often
intersect in stem and progenitor cells and regulate each other
transcriptionally, the biological outcome of signalling through
each pathway often depending on the context and timing.
Thus, these findings need to be investigated more in details.
Finally, we obtained interesting results about the imprinted
locus at chr 11p15.5. Specifically, we observed in this region
(including the genes IGF2, IGF2AS, INS, INS-IGF2, and
MIR483) frequent cnLOH or LOH associated with CN loss in
ACC (54% and 23% of cases, respectively) and CN gains in
25% of ACA. Thus, we could hypothesize that a CN gain at this
locus could be an early alteration in a multi-step tumor
progression (already present in benign tumors), while the
following loss of an allele leading to a cnLOH could represent a
second hit, leading to the increased IGF2 expression only in
malignant tumors. An additional CN loss could then here
somehow represent a final step, but without further modifying
the IGF2 expression levels (Figure 7B). These findings are of
particular interest because the human chr 11p15.5 contains a
cluster of imprinted genes (organized in two neighbouring
imprinted domains, the IGF2/H19 and the KCNQ1OT1/
CDKN1C) that play a crucial role in the development of many
organ systems, including the adrenal cortex. Aberrations of the
11p15 region were found in both Beckwith–Wiedemann and
Silver–Russell syndromes [57], and were also reported by SNP
array profiling in childhood adrenocortical tumors [41]. Loss of
imprinting has also been reported in colorectal carcinomas,
Wilm’s tumor, esophageal carcinoma, childhood acute
lymphoblastic leukemia, and prostate cancer. In cells that
express both parental IGF2 alleles, the increase in IGF2
production may be a mechanism for promoting cancer
development [58]. Structural and functional abnormalities at
11p15 are associated with the malignant phenotype in sporadic
adrenocortical tumors [59] and IGF2 expression is dramatically
up-regulated in at least 80% of sporadic ACCs, compared with
either ACA or normal adrenal tissue [60,61]. Finally, a recent
paper showed that a mouse model with a combination of
stabilized β-catenin and elevated IGF2 expression presented
larger adrenal glands, displayed earlier onset of hyperplasia,
and developed more frequent macroscopic adenomas (as well
as one carcinoma) than the models with only one alteration,
suggesting the need of an accumulation of a second or multiple
alterations for tumorigenesis [10]. Similarly, another study
analysed the role of IGF2 in transgenic mouse models and
demonstrated that IGF2 over-expression even in combination
with costitutive β-catenin activation, is only a mild contributor to
malignant adrenocortical tumorigenesis, suggesting the
involvement of multiple other factors [62]. Thus, we postulate a
multi-step adenoma carcinoma sequence for adrenocortical
tumors, although we are aware that the progression of
adenoma to carcinoma is a rare event.
Alterations potentially useful as diagnostic markers
(different between ACA and ACC)
A series of genetic alterations detected with the SNP array
analysis were found to be unique in malignant tumors. For
instance, the amplification of more than 60% of the chr 5 was
observed only in ACC. This finding was also confirmed at the
FISH analysis, which could be suggested as a cheap and fast
method for the identification of chr 5 amplification in
adrenocortical tumors. Similar findings (i.e. CN gain of chr 5p)
have been already reported in other cancer types, such as the
cervical cancer [63], and also in adrenocortical cancer, but only
together with other chromosomes (i.e. 4, 7, 12 and 19 [41,64])
and not as playing a major role. Thus, importantly, this kind of
alteration could be used as a new differential diagnostic marker
(sensitivity 77.3% and specificity 100%).
As far as the specific CN analysis is concerned, recurrent CN
losses were completely absent in ACAs, which shows that they
are rather specific for ACCs. In addition, the simultaneous
presence of more than 50 large CNA (>100 Kb) and more than
10 LOH events resulted to be highly specific for ACC
(sensitivity 82% and specificity 100%, Figure 5). This genetic
pattern might be also used as a new marker for malignancy.
In terms of enrichment analysis, over 160 gained oncogenes,
20 lost tumor suppressor genes and 67 tumor suppressor
genes affected by cnLOH were identified only in carcinomas.
Some of these genes (i.e. MYC, MDM2, PDGFRA, and KIT
among gained genes and RB1 and TP53 in lost genes) have
been found also in childhood tumors [41], suggesting some
common genetic alterations between children and adults. The
most frequently altered pathways specific for malignant tumors
were related to cell adhesion, apoptosis and survival,
cytoskeleton remodeling, development, signal transduction,
and immune response.
Alterations potentially useful as prognostic factors
(related to survival in ACC)
A specific combination of chromosomes with large CNA (i.e.
large amplification at chr 5, 7, 12, and 19, and large deletions
at chr 1, 2, 13, 17, and 22) was associated with a better
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prognosis, while a random pattern of alterations in the whole-
genome seem to be correlated with a poorest survival. These
findings may suggest a relationship between a specific genetic
pattern and the overall clinical outcome, but need to be
validated in a larger patient cohort and better investigated with
further experiments.
In conclusion, by using high-resolution SNP array analysis,
we identified some genes and pathways, such as the Notch
signaling, which were similarly altered in ACA and ACC. Our
findings suggest a potential major role for these alterations in
early tumorigenesis and provide new insight on a postulated
adenoma-carcinoma sequence in adrenocortical tumors. In
general, our study can serve as a database for the
identification of interesting genes and pathways involved in
adrenal tumor development and progress. Moreover, some
genetic alterations, such as large CNA (including the
amplification of the chr 5 and huge losses) and LOH events,
were restricted to the ACC and could serve as diagnostic
markers for malignancy.
Supporting Information
Figure S1.  Principal component analysis for the SNP array
analysis of 46 adrenocortical tumors (24 adenoma in blue
and 22 carcinoma in red) by Partek Genomic Suite
Software.
(TIF)
Figure S2.  Enrichment analysis including the genes with
copy number alterations observed only in carcinomas
(recurrent CNA, in at least 4 samples). A) Analysis
generated including genes affected by copy number gains
(n=11414). B) Analysis generated including genes affected by
copy number gains (n=3717). Gene family analysis by GSEA;
pathway and gene process analysis by GeneGo (Meta Core
Analytical suite, P values expresses as logarithmic scale;
detailed legend available at http://pathwaymaps.com/pdf/
MC_legend.pdf.).
(PPT)
Figure S3.  A) Results of the generation of biological networks
using Analyze Networks (AN) algorithm with default settings.
The gene content of the uploaded files (genes with LOH events
observed in at least 4 samples in carcinomas, n=11415) is
used as the input list. This is a variant of the shortest paths
algorithm with main parameters of 1. relative enrichment with
the uploaded data, and 2. relative saturation of networks with
canonical pathways. In this workflow the networks are
prioritized based on the number of fragments of canonical
pathways on the network. B) Graphical representation of the
top scored (by the number of pathways) analysed network
(positive regulation of the macromolecule metabolic process).
Thick cyan lines indicate the fragments of canonical pathways.
Up-regulated genes are marked with red circles; down-
regulated with blue circles. The 'checkerboard' color indicates
mixed expression for the gene between files or between
multiple tags for the same gene. Detailed legend is available at
http://pathwaymaps.com/pdf/MC_legend.pdf.
(PPT)
Table S1.  List of all the copy number alterations detected
in 46 adrenocortical tumors by SNP array profile, including
the relative chromosomal regions, length, type of
alteration, number of markers, intensity score (mean) and
corresponding genes. A) adenomas (n=24); B) carcinomas
(n=22).
(XLS)
Table S2.  List of all the copy number alterations detected
in at least 4 samples among 46 adrenocortical tumors by
SNP array profile (minimal overlapping regions, frequency
> 13%), including the relative chromosomal regions,
length, type of alteration, intensity score (average) and
corresponding genes. A) adenomas (n=24); B) carcinomas
(n=22).
(XLS)
Table S3.  List of copy number alteration (all gains) in
common between adrenocortical adenomas (n=24) and
carcinomas (n=22), including the chromosomal regions,
length of intersection, overlap percentage and
corresponding genes.
(XLS)
Table S4.  List of loss of heterozygosity (LOH) events in
common between adrenocortical adenomas (n=24) and
carcinomas (n=22), including the chromosomal regions,
overlap percentage and corresponding genes.
(XLS)
Table S5.  Gene family analysis (GSEA) of all the most
frequently altered genes observed at the SNP array
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